How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.

Buy: Anthropic exposure via its likely IPO/secondary path (e.g., IPO allocation or liquid proxy like AI-safety/compute beneficiaries). Rationale: Anthropic is pushing “slow/pause” policy while still ...

One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Lets geek out. The HackerNoon library is now ranked by reading time created. Start learning by what others read most. Lets geek out. The HackerNoon library is now ranked by reading time created. Start ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

The application of deep learning algorithms in protein structure prediction has greatly influenced drug discovery and development. Accurate protein structures are crucial for understanding biological ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Erik Steiger discusses the operational pain ...

This important computational study provides new insights into how neural dynamics may lead to time-evolving behavioral errors as observed in certain working-memory tasks. By combining ideas from ...